背景:肥胖与许多慢性非传染性疾病相关,包括高血压,糖尿病,心脑血管疾病,癌症,胆囊疾病,骨骼和关节疾病,皮肤病,脂肪肝,等。[1]最近的报告显示,60%的成年人群普遍存在超重和肥胖。已经发表了几项研究来确定木薯sabdarifaLinn的效果。关于肥胖治疗,但是调查结果仍然没有定论。这项研究的目的是确定H.sabdarifaLinn治疗肥胖症的疗效和安全性。
方法:我们搜索了PubMed,EMBASE,和中央从成立到2024年2月。如果研究H.sabdariffa对以下结果之一的影响,则纳入随机对照试验(RCT):体重,体重指数(BMI),腰围,和腰臀比.使用随机效应模型对数据进行荟萃分析。I2用于量化所包括的RCT之间的统计异质性。PROSPERO注册协议:CRD42023408880。
结果:共纳入6个RCT,339名参与者。与安慰剂相比,四项试验在胶囊中使用H.sabdariffa提取物作为感兴趣的干预措施,而其他两项试验使用H.sabdarifa茶与红茶或绿茶相比。我们的荟萃分析显示,H.sabdariffa和对照组之间体重减轻的平均差异为-0.27千克(95%置信区间(CI);-1.98至1.42,I2=0.0%)。BMI和腰围减少的平均差异为-0.06千克/米2(95%CI;-0.58至0.47,I2=0.0%)和-0.20厘米(95%CI;-2.06至1.66,I2=0.00%)。在纳入的研究中没有报告安全性问题。
结论:我们的研究未显示H.sabdarifa提取物在肥胖治疗中的临床益处。然而,仍然需要更多的高质量RCTs,治疗时间更长,剂量标准.
BACKGROUND: Obesity is associated with many chronic non-communicable diseases, including hypertension, diabetes, cardiovascular and cerebrovascular diseases, cancer, gallbladder disease, bone and joint disorders, skin diseases, fatty liver disease, etc. (Wharton et al., 2020)1 The recent report revealed that overweight and obesity were prevalent in 60 % of the adult population. Several studies have been published to determine the effect of Hibiscus sabdariffa Linn. on obesity treatment, but the findings are still inconclusive. The purpose of this study was to determine the efficacy and safety of H. sabdariffa Linn in the treatment of obesity.
METHODS: We searched PubMed, EMBASE, and CENTRAL from inception to February 2024. Randomized controlled trials (RCTs) were included if they explored the effect of H. sabdariffa on one of the following outcomes: body weight, body mass index (BMI), waist circumference, and waist-to-hip ratio. A random-effects model was used to meta-analyze the data. I2 was used to quantify statistical heterogeneity among the included RCTs. PROSPERO registered protocol: CRD42023408880.
RESULTS: A total of six RCTs with 339 participants were included. Four trials used H. sabdariffa extract in capsules as the intervention of interest compared to placebo, while the other two trials used H. sabdariffa tea compared to black or green tea. Our meta-analyses showed that the mean difference in weight reduction between H. sabdariffa and control was - 0.27 kg (95 % confidence interval (CI); - 1.98 to 1.42, I2 = 0.0 %). The mean differences for BMI and waist circumference reduction were - 0.06 kg/m2 (95 % CI; - 0.58 to 0.47, I2 = 0.0 %) and - 0.20 centimeters (95 % CI; - 2.06 to 1.66, I2 = 0.00 %). No safety concerns were reported in the included studies.
CONCLUSIONS: Our study did not show a clinical benefit of H. sabdariffa extract in obesity treatment. However, further high-quality RCTs with a longer treatment duration and a standard dose are still warranted.